Skip to main content

Biosimilars: from concern to confidence



A blended education program designed by Springer Healthcare IME, in collaboration with Dr Paul Cornes, for all medical oncologists, specialist nurses and allied healthcare professionals (HCPs) working with patients for whom biosimilars may represent a treatment option.

Despite their promise, the uptake, and therefore benefits, of biosimilars in oncology has been slower than expected. A key barrier to their uptake is low HCP knowledge and acceptance of the concept of biosimilarity. Despite an increase in medical education, there are several clinical and non-clinical factors that contribute to a lack of confidence among HCPs.

This program aims to provide HCPs with a better understanding of the biosimilar development process and extrapolation of indications concept, and to help improve their confidence in prescribing biosimilars to their patients. Our goal is to focus on the key issues from the HCP point of view in order to support them in resolving and overcoming these barriers.

Would you like to know more?

Enter your details to be the first to know about this new educational content

Sign up here

Program at-a-glance

eLearning modules

A range of 6 eLearning modules will focus on various aspects of biosimilars in oncology through a combination of expert video interviews and engaging assessment tools to effectively relay messages and gauge learner knowledge.

The eLearning modules will include the following hot topics:

  • Data analytics
  • Extrapolation of indications
  • Key issues affecting clinician, nurse and patient confidence
  • Patient communication


A filmed expert panel discussion. As the use of biosimilars is advanced further in the rheumatology setting, a specialist rheumatologist will share their insights and experiences with leading oncologists to debate the potential issues arising for oncology HCPs in the near future.

Learning objectives

On completion of the eLearning modules and webcast, learners will be able to: 

  • Explain the analytical process in the development of biosimilars and the concept of extrapolation of indications;
  • Gain confidence in the use of biosimilars and build confidence amongst their peers, with the support of rheumatologist advice;
  • Debate the best practice in patient communication in initiation or switching to a biosimilar product.

Program director

Dr Paul Cornes

Oncologist, Comparative Outcomes Group, Bristol, UK

Dr Paul Cornes (BM BCH MA MRCP FRCR) has trained in Medicine at Oxford University and in Oncology at the Royal Marsden Hospital, London, UK before becoming a Consultant Oncologist in Bristol, UK.

Read more

Educational funding

This program has been made possible thanks to an independent educational grant from Pfizer.


An application will be made to the EACCME® for CME accreditation of the eLearning modules and webcast.

Contact us

Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK


Image Credits